Seegene Reveals New Real-Time PCR at AACC 2014

Seegene Inc. (Eschborn, Germany), a developer of multiplex PCR technologies, revealed their “MuDT” technology at the AACC 2014 meeting. MuDT is a real-time polymerase chain reaction (PCR) technology that will cause a shift in the PCR instrument market. The technology doubles the multiplexing capacity of any existing real-time PCR instrument––thus maximizing the value of the installed base of these instruments.

MuDT technology can be applied to any existing real-time PCR instrument and transforms it into a more powerful system by doubling its multiplexing capacity without upgrading the hardware.

The biotechnology industry has relied on real-time PCR for at least 20 years a molecular diagnostics technology, because of its versatility, speed, and ease of use. Despite many attempts, the biotechnology industry has not made significant advances that satisfy the growing demand for increased multiplexing and target quantification using limited numbers of channels in a single tube. Even melt curve analysis, after amplification has many disadvantages, such as end-point analysis after amplification, extended turnaround time, lack of quantification, and melt temperature variation due to target sequence variations on probe binding regions.

Additional benefits of the technology include: easier detection of multiple targets in a single channel without requiring melt curve analysis after amplification, SNP genotyping (homozygous wild type or mutant, or heterozygous) in a single channel.

Seegene is a global developer of multiplex molecular technologies and multiplex clinical molecular diagnostics that can simultaneously detect multiple targets with sensitivity, specificity, and reproducibility. The company's products detect multipathogens with good reliability and throughput, ultimately providing an economical basis for saving time, labor, and cost.

Related Links:
Seegene